deltatrials
Terminated PHASE2 NCT00109772

Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1

A Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Complex Regional Pain Syndrome Type 1

Sponsor: Celgene Corporation

Conditions Complex Regional Pain Syndrome, Type I
Interventions Placebo lenalidomide
Updated 7 times since 2017 Last updated: Aug 26, 2013 Started: Feb 28, 2005 Primary completion: Apr 30, 2008 Completion: Apr 30, 2008

Listed as NCT00109772, this PHASE2 trial focuses on Complex Regional Pain Syndrome, Type I and remains terminated or withdrawn. Sponsored by Celgene Corporation, it has been updated 7 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

  2. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Feb 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Celgene Corporation
Data source: Celgene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Allentown, United States, Baltimore, United States, Boston, United States, Chapel Hill, United States, Charlottesville, United States, Chicago, United States, Dallas, United States, Dayton, United States, Durham, United States, Fort Bragg, United States and 15 more location s